SEARCH

SEARCH BY CITATION

References

  • 1
    Baum M. Renal Fanconi syndrome secondary to deferasirox: where there is smoke there is fire. J Pediatr Hematol Oncol. 2010; 32: 5256.
  • 2
    Even-Or E, Becker-Cohen R, Miskin H. Deferasirox treatment may be associated with reversible renal Fanconi syndrome. Am J Hematol. 2010; 85: 1324.
  • 3
    Rafat C, Fakhouri F, Ribeil JA, Delarue R, Le Quintrec M. Fanconi syndrome due to deferasirox. Am J Kidney Dis. 2009; 54: 9314.
  • 4
    Yacobovich J, Stark P, Barzilai-Birenbaum S, Krause I, Pazgal I, Yaniv I, Tamary H. Acquired proximal renal tubular dysfunction in β-thalassemia patients treated with deferasirox. J Pediatr Hematol Oncol. 2010; 32: 5647.
  • 5
    Brittenham GM. Iron-chelating therapy for transfusional iron overload. N Engl J Med. 2011; 364: 14656.
  • 6
    Mohkam M, Shamsian BS, Gharib A, Nariman S, Arzanian MT. Early markers of renal dysfunction in patients with beta-thalassemia major. Pediatr Nephrol. 2008; 23: 9716.
  • 7
    Ponticelli C, Musallam KM, Cianciulli P, Cappellini MD. Renal complications in transfusion-dependent beta thalassaemia. Blood Rev. 2010; 24: 23944.
  • 8
    Economou M, Printza N, Teli A, Tzimouli V, Tsatra I, Papachristou F, Athanassiou-Metaxa M. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. Acta Haematol. 2010; 123: 14852.
  • 9
    Sumboonnanonda A, Malasit P, Tanphaichitr VS, Ong-ajyooth S, Sunthornchart S, Pattanakitsakul S, Petrarat S, Assateerawatt A, Vongjirad A. Renal tubular function in β-thalassemia. Pediatr Nephrol. 1998; 12: 2803.
  • 10
    Hamed EA, El Melegy NT. Renal functions in pediatric patients with beta-thalassemia major: relation to chelation therapy: original prospective study. Ital J Pediatr. 2010; 36: 39.
  • 11
    Smolkin V, Halevy R, Levin C, Mines M, Sakran W, Ilia K, Koren A. Renal function in children with β-thalassemia major and thalassemia intermedia. Pediatr Nephrol. 2008; 23: 184751.
  • 12
    Aldudak B, Karabay Bayazit A, Noyan A, Ozel A, Anarat A, Sasmaz I, Kilinç Y, Gali E, Anarat R, Dikmen N. Renal function in pediatric patients with β-thalassemia major. Pediatr Nephrol. 2000; 15: 10912.
  • 13
    Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Athanassiou-Metaxa M, Giardina P, Kourakli-Symeonidis A, Janka-Schaub G, Coates T, Vermylen C, Olivieri N, Thuret I, Opitz H, Ressayre-Djaffer C, Marks P, Alberti D. Aphase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood. 2006; 107: 345562.
  • 14
    Yew CT, Talaulikar GS, Falk MC, Clayton P, D'Rozario J, Brown M. Acute interstitial nephritis secondary to deferasirox causing acute renal injury needing short-term dialysis. Nephrology. 2010; 15: 377.
  • 15
    Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab. 2009; 94: 2332237.
  • 16
    Sekine T. Rickets/osteomalacia due to tubular dysfunction. Clin Calcium. 2007; 17: 152933.
  • 17
    Tiosano D, Hochberg Z. Hypophosphatemia: the common denominator of all rickets. J Bone Min Metab. 2009; 27: 392401.
  • 18
    Clarke BL, Wynne AG, Wilson DM, Fitzpatrick LA. Osteomalacia associated with adult Fanconi's syndrome: clinical and diagnostic features. Clin Endocrinol. 1995; 43: 47990.
  • 19
    Bhambri R, Naik V, Malhotra N, Taneja S, Rastogi S, Ravishanker U, Mithal A. Changes in bone mineral density following treatment of osteomalacia. J Clin Densitom. 2006; 9: 1207.